Tennessee Clinical Trials

A listing of Tennessee clinical trials actively recruiting patient volunteers.

Tennessee is a lively and lovely state known as the birthplace of bluegrass and the site of Graceland and Dollywood. It's also the place to go to see one of America's most iconic national parks, The Great Smoky Mountain National Park. Nashville is where you can immerse yourself in the history of the music business, while Memphis, Knoxville, and Gatlinburg each offer their own perks and sights. In any of these cities and beyond, sound healthcare is easy to find. Vanderbilt University Medical Center has been ranked #1 in the state, with more than 1,000 acute care beds in service.

Search by Name
Search
Filter by Condition
2204 trials found

REACH Hope Intervention for Dementia and TBI Caregivers

NCT04969796

This three-year randomized clinical trial will evaluate a behavioral intervention for caregivers of Veterans with traumatic brain injury (TBI) and Alzheimer's dementia or mixed Dementia (AD/MD) to reduce caregiver depression, anxiety and burden, and improve veterans' health management. The study will combine and deliver two award-winning behavioral interventions - REACH VA (Resources for Enhancing All Caregivers Health in Department of Veterans Affairs) and the DoD's Virtual Hope Box, which we c ...

Conditions: Dementia, Mixed, Dementia of Alzheimer Type, TBI (Traumatic Brain Injury)
Phase: Not Applicable

Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785

The primary objective of this study is to evaluate whether the combination of semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR) causes fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with compensated cirrhosis due to NASH.

Conditions: Nonalcoholic Steatohepatitis

Trial of PDE4 Inhibition With Roflumilast for the Management of Seborrheic Dermatitis (STRATUM)

NCT04973228

The study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once for 8 weeks by subjects with seborrheic dermatitis.

Conditions: Seborrheic Dermatitis

Diabetes Medical Nutrition Therapy in Southeastern African American Women

NCT04971889

A two-arm randomized controlled trial design will be used. Participants will include 291 African American women with type 2 diabetes that are at risk for development and/or progression of diabetes complications. Both arms, diabetes medical nutrition therapy (MNT) and diabetes MNT plus motivational interviewing (MI), will include: 1) a 3-month active intervention period of six biweekly (every other week), group-based, trained nutritionist-facilitated sessions; 2) a 3-month maintenance interventio ...

Conditions: Type 2 Diabetes
Phase: Not Applicable

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.

Conditions: Light Chain (AL) Amyloidosis

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

NCT04972968

Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older. This study evaluates how safe and effective ABBV-154 is in participants with glucocorticoid-dependent PMR. Adverse events and change in disease activity will be assessed. ABBV-154 is an investigational drug being evaluated for the treatment of PMR. Participants will be randomized into 1 of 4 treatment groups or arms, each arm receiving a different treatme ...

Conditions: Polymyalgia Rheumatica

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

NCT04976803

This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Conditions: Solid Tumor, Unspecified, Adult

Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses

NCT04980456

The purpose of this study is to compare the clinical performance of TOTAL30 contact lenses with Biofinity contact lenses over 30 days of daily wear.

Conditions: Myopia
Phase: Not Applicable

A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

NCT04983589

Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). AGN-190584 is an investigational drug being developed for the treatment of presbyopia. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatm ...

Conditions: Presbyopia

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

NCT04986202

This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction > 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 825 in Part B.

Conditions: Heart Failure With Preserved Ejection Fraction
Phase: Phase 2/3

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

NCT04988997

A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.

Conditions: Short Bowel Syndrome

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

NCT04988867

To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls with Rett syndrome

Conditions: Rett Syndrome
Phase: Phase 2/3